Takeda Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (172)

Electronic Access - Single User License $800 Buy Now
CD-ROM Mail Delivery $1200Buy Now
Hard Copy Mail Delivery $1200 Buy Now
Electronic Access - Multi-User License $1600 Buy Now


“Takeda -Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Takeda. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “27” cancer drugs in clinical pipeline and majority of them are in research phase. There are 16 cancer drugs by Takeda which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Takeda -Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Takeda -Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Takeda. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “27” cancer drugs in clinical pipeline and majority of them are in research phase. There are 16 cancer drugs by Takeda which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Takeda -Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Takeda

  1.1 Business Overview

  1.2 Takeda Cancer Pipeline Overview

 

2. Takeda Cancer Drugs in Research Phase

  2.1 Anticancer Therapeutics - Tri-Institutional Therapeutics Discovery Institute/Takeda

  2.2 Antibody Therapeutics - Adimab/Takeda

  2.3 RNAi Therapeutics - Alnylam/Takeda

  2.4 Mitochondrial Therapeutics- Gencia/ Takeda

  2.5 Anti-Cancer Therapeutics - National Cancer Center (Tokyo)/Takeda

  2.6 Induced Pluripotent Stem Cell Therapeutics - Center for iPS Cell Research Application/Takeda

  2.7 Therapeutic Monoclonal Antibodies - Takeda/XOMA

 

3. Takeda Cancer Drugs in Preclincal Phase

  3.1 Cenicriviroc

  3.2 Phosphatidylinositol 3 Kinase Inhibitors - Infinity Pharmaceuticals

  3.3 Targeted Nanoparticle Therapeutics - BIND Therapeutics

  3.4 raf Kinase Inhibitor – Takeda

  3.5 Antibody-Drug Conjugates - Adimab/Mersana Therapeutics

  3.6 Protein Kinase Inhibitors - Millennium/Sunesis/Supernus

 

4. Takeda Cancer Drugs in Clinical Phase

  4.1 Brentuximab Vedotin Companion Diagnostic - Ventana Medical Systems

 

5. Takeda Cancer Drugs in Phase-I

  5.1 Vedolizumab

  5.2 RAD 1901

  5.3 Plozalizumab

  5.4 TAK 580

  5.5 TAK 931

  5.6 IPI 549

  

6. Takeda Cancer Drugs in Phase-I/II

  6.1 Mapatumumab

 

7. Takeda Cancer Drugs in Phase-II

  7.1 Relugolix

  7.2 Sapanisertib

  7.3 Alisertib

  7.4 TAK 117

  7.5 Pevonedistat

 

8. Takeda Cancer Drugs in Phase-III

  8.1 Duvelisib

 

9. Marketed Cancer Drugs by Takeda

  9.1 Bortezomib (Velcade)

  9.2 Panitumumab (Vectibix)

  9.3 Ixazomib (NINLARO)

  9.4 Rituximab (MabThera & Rituxan)

  9.5 Ibandronic Acid (Bondronat, Boniva & Bonviva)

  9.6 Bendamustine (Bendam, Bendamus, Bentaman, Endexin, Esevaril, Innomustine, Levact, Ribomustin, Ribomustine, Ribovact, Symbenda, Treakisym & Treanda)

  9.7 Brentuximab Vedotin (Adcetris)

  9.8 Triptorelin (ARVEKAP, Decapeptyl, Decapeptyl SR, Diphereline, Moapar, Pamorelin, Pamorelin LA, Salvacyl, Trelstar & Trelstar Depot)

  9.9 Porfimer Sodium (Photobarr, Photofrin, Photofrin II & Photofrin PDT)

  9.10 Calcium Levofolinate (FUSILEV & Isovorin)

  9.11 Gemtuzumab Ozogamicin (Mylotarg)

  9.12 Mifamurtide (Junovan & Mepact)

  9.13 Leuprorelin Depot (Carcinil, Enanton Depot, Enanton-Gyn, Enantone, Enantone Depot, Enantone LP, Ginecrin, Leuplin, Leuplin SR, Lucrin, Lucrin Depot, Lupron Depot, Lupron Depot-PED, Procren Depot, Procrin, Prostap SR & Trenantone-Gyn)

  9.14 Temsirolimus (Torisel)

  9.15 Raloxifene (Celvista, Evista, Optruma & Sevista (raloxifene))

  9.16 Mitoxantrone (Novantron, Novantrone, Onkotrone & Pralifan)

  

10. No Development Reported in Cancer Drugs in Clinical Pipeline

  10.1 Nomegestrol Oral

  10.2 H 447

  10.3 TAK 901

  10.4 Histone Deacetylase Inhibitors - Roche/Takeda San Diego

  10.5 RNAi Therapeutics - Samyang/Takeda

  10.6 Anticancer Therapeutics – Takeda

  10.7 Anticancer Antibodies - ARIUS/Takeda

  10.8 Ubiquitin-Proteasome Inhibitors - Takeda Oncology

  10.9 Cancer Therapeutics – Takeda

  10.10 Metastin – Takeda

  10.11 AG 2000

  10.12 B 9109012

  10.13 GS 198

  10.14 TAN 1120

  10.15 Phosphatidylinositol 3 Kinase Alpha Inhibitors - Intellikine/Numerate

  10.16 Drug Discovery - BC Cancer Agency/Takeda

 

11. Discontinued in Cancer Drugs in Clinical Pipeline

  11.1 Bosentan

  11.2 Ulipristal

  11.3 Ganitumab

  11.4 TAK 448

  11.5 Orteronel

  11.6 Motesanib

  11.7 IDM 1

  11.8 Conatumumab

  11.9 Matuzumab

  11.10 TAK 114

  11.11 Docebenone

  11.12 MDX 210

  11.13 IDM 5

  11.14 CV 6504

  11.15 MDX 220

  11.16 AGM 1470

  11.17 Melanoma Vaccine – Epimmune

  11.18 Dexniguldipine

  11.19 TNP 351

  11.20 TAK 683

  11.21 TAK 733

  11.22 TAK 285

  11.23 TAK 810

  11.24 Mubritinib

  11.25 A 84861

  11.26 IDD 6

  11.27 Cell-Based Anticancer Therapeutic – IDM

  11.28 Cancer Vaccine - IDM S.A./Oxford BioMedica

  11.29 Prostate Cancer Vaccine – Epimmune

  11.30 TAN 1496E

  11.31 TAN 1518B

  11.32 TAN 1323C

  11.33 TAN 1323D

  11.34 TAN 1518A

  11.35 TAN 1496C

  11.36 TAN 1496A

  11.37 TAN 1057A

  11.38 TAN 999


Figure 1-1: Takeda Cancer Pipeline by Phase (%)

Figure 1-2: Takeda Cancer Clinical Pipeline by Phase (Number)

Figure 1-3: Takeda Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Takeda Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)